Please ensure Javascript is enabled for purposes of website accessibility

Why Diabetes Stock Dexcom Jumped 14.6% in February While the Market Dropped

By Beth McKenna - Mar 6, 2020 at 8:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the medical device maker bucked the coronavirus-driven market sell-off.

What happened

Shares of medical device maker Dexcom, Inc. (DXCM -0.69%) gained 14.6% in February, according to data from S&P Global Market Intelligence

That performance is even stronger than it might initially seem considering the S&P 500 index dropped 8.2% last month due to concerns that the novel coronavirus, COVID-19, could blunt global economic growth. 

Dexcom stock is up a whopping 95.1% over the one-year period through March 5, compared to the broader market's 10.6% return over this period.

The G6 continuous glucose monitor and various smart watches and phones.

Image source: Dexcom.

So what

We can attribute Dexcom stock's strong performance last month to the healthcare company's Feb. 13 release of fourth-quarter 2019 results that pleased investors. Shares soared 12.6% the next day.

In Q4, revenue jumped 37% year over year to $462.8 million, driven by the continued robust demand from people living with diabetes for the company's G6 continuous glucose monitoring (CGM) systems. That result easily topped the $442.4 million Wall Street consensus estimate. Adjusted earnings came in at $106.5 million, or $1.15 per share, up from $50.2 million, or $0.56 per share, in the year-ago period. That result also sprinted by the analyst expectation, which was $0.74.

DXCM Chart

Data by YCharts.

Now what

Dexcom reaffirmed its guidance for full-year 2020. It expects revenue of $1.73 billion to $1.78 billion, representing growth of 17% to 20% year over year. It also projects adjusted operating margin of approximately 13%, compared to 10.9% in 2019.

Beth McKenna has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DexCom, Inc. Stock Quote
DexCom, Inc.
DXCM
$87.53 (-0.69%) $0.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.